LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

Accueil・Liste d'Actions・Erasca Inc

Erasca Inc

Ouvert

10.25 -0.58

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

10.49

Chiffres clés
By Trading Economics
Revenu	1.5M -29M
Employés	103
EBITDA	-2M -32M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+85.32% upside

Dividendes
By Dow Jones
Prochains Résultats	11 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-1.7B 3.2B
Ouverture précédente	10.83
Clôture précédente	10.25

Score Technique

By Trading Central

Confiance

Bearish Evidence

1.39 / 1.44 Support & Résistance

Erasca Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 mai 2026, 23:58 UTC

Résultats

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mai 2026, 22:57 UTC

Résultats

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mai 2026, 23:52 UTC

Résultats

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mai 2026, 23:11 UTC

Résultats

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mai 2026, 23:06 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mai 2026, 23:05 UTC

Résultats

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mai 2026, 23:04 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mai 2026, 23:03 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mai 2026, 23:03 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mai 2026, 23:02 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mai 2026, 22:42 UTC

Résultats

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mai 2026, 22:33 UTC

Résultats

Acquisitions, Fusions, Rachats

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:32 UTC

Résultats

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mai 2026, 22:31 UTC

Résultats

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mai 2026, 22:31 UTC

Résultats

Macquarie: 68% of FY Income From International >MQG.AU

7 mai 2026, 22:30 UTC

Résultats

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mai 2026, 22:30 UTC

Résultats

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mai 2026, 22:29 UTC

Résultats

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mai 2026, 22:28 UTC

Résultats

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mai 2026, 22:28 UTC

Résultats

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mai 2026, 22:27 UTC

Résultats

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mai 2026, 22:27 UTC

Résultats

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mai 2026, 22:26 UTC

Résultats

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mai 2026, 22:25 UTC

Résultats

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparaison

Variation de prix

Erasca Inc prévision

Objectif de Prix

By TipRanks

85.32% hausse

Prévisions sur 12 Mois

Moyen 20.2 USD 85.32%

Haut 30 USD

Bas 9 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.39 / 1.44Support & Résistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.